Top Markets
Coin of the day
Mustang Bio, Inc. Mustang Bio, Inc.

Mustang Bio, Inc.

MBIO
Rank in Stocks #35075
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Share Price
$0.594
Last synced: 2026-08-14
Market Cap
$4.50M
Change (1 day)
0.00%
Change (1 year)
-66.44%
Country
US
Trade Mustang Bio, Inc. (MBIO)

Category

Stock price history for Mustang Bio, Inc. (MBIO)
Highest end of day price: $0.60 on 2026-08-01

Lowest end of day price: $8.92K on 2017-08-01
Stock price history of Mustang Bio, Inc. from 2017 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -10.26%
2025 -87.55%
2024 -86.83%
2023 -76.52%
2022 -79.00%
2021 -45.05%
2020 -1.99%
2019 18.38%
2018 -73.75%
2017 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE